Do you want to read an article? Please log in or register.
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Related content
Lipid-Lowering DrugsTherapy and Intervention
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
JAMA Cardiol.
Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS
doi: 10.1001/jamacardio.
RECOMMENDED
Lipid-Lowering Drugs
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
N Engl J Med.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP, ORION-10 and ORION-11 Investigators
doi: 10.1056/NEJMoa1912387.
COMMENTED
Lipid-Lowering Drugs
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Eur Heart J.
Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG
doi: 10.1093/eurheartj/ehy334.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA.
Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB
doi: 10.1001/jama.2019.16585.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
RECOMMENDED
Lipid-Lowering Drugs
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control
Atherosclerosis.
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP
doi: 10.1016/
Cardiovascular Risk and Diseases
Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium
Lancet.
Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S, Thorand B, Giampaoli S, Brambilla P, Tunstall-Pedoe H, Moitry M, Iacoviello L, Veronesi G, Grassi G, Mathiesen EB, Söderberg S, Linneberg A, Brenner H, Amouyel P, Ferrières J, Tamosiunas A, Nikitin YP, Drygas W, Melander O, Jöckel KH, Leistner DM, Shaw JE, Panagiotakos DB, Simons LA, Kavousi M, Vasan RS, Dullaart RPF, Wannamethee SG, Risérus U, Shea S, de Lemos JA, Omland T, Kuulasmaa K, Landmesser U, Blankenberg S, Multinational Cardiovascular Risk Consortium.
doi: 10.1016/S0140-6736(19)32519-X.
Heart, Artery and Coronary DiseasesLipid-Lowering DrugsMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
N Engl J Med.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators
doi: 10.1056/NEJMoa1609581.
RECOMMENDED
Cardiovascular Risk and DiseasesMyocardial Infarction
Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet
Mortensen MB, Nordestgaard BG
doi: 10.1016/S0140-6736(20)32233-9